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We would like to commend the editors for highlighting the usually silent issue of treatment differences in affluent vs developing societies 1 and stimulating discussion on such an important topic. We were, however, intrigued to read in the editorial that chronic myeloid leukaemia (CML) is the commonest childhood leukaemia in India rather than the 'usual' adult onset. The authors of this letter have worked in India, including one of the authors (CMP) for B35 years, and have never seen CML as the most common type of leukaemia in children, which they believe has always been acute lymphoblastic leukaemia. We agree that the epidemiological literature on the incidence of haematological malignancies in India is sparse, but even in the reported literature, CML is not seen in children and has an epidemiology that is similar to that seen in the West. [2] [3] [4] We accept the fact that most government teaching hospitals come across numerous cases of chronic malignancies, where there is enough time for a patient to travel long distances, and a number of patients of acute leukaemia may be dying before receiving medical attention in rural areas. We are happy that the editors are optimistic on the treatment question but beg to differ that 80% of Indians cannot afford to pay for simple medicines, let alone an allogeneic transplant, which, even in the cost-constrained Indian scenario, would cost upwards of d3000, and further added costs of immunosuppression and treatment of infections. Busulphan and hydroxyurea still remain the treatment of choice for a majority of patients despite all the advances in CML. The Development of cheaper economic models of treatment, preferably 'single-shot' options, would be a major step forward.
AD Wechalekar
1 and CM Parande
